dacarbazine and cblc137

dacarbazine has been researched along with cblc137 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Barone, TA; Burkhart, CA; Gudkov, AV; Gurova, KV; Haderski, G; Plunkett, RJ; Purmal, AA; Safina, A	1

Other Studies

1 other study(ies) available for dacarbazine and cblc137

Article	Year
Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma. Neuro-oncology, 2017, 02-01, Volume: 19, Issue:2 Topics: Animals; Antineoplastic Agents; Apoptosis; Blood-Brain Barrier; Brain Neoplasms; Carbazoles; Cell Proliferation; Dacarbazine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Female; Glioblastoma; High Mobility Group Proteins; Humans; Mice; Mice, Nude; Temozolomide; Transcriptional Elongation Factors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2017

Article

Year

Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.

Neuro-oncology, 2017, 02-01, Volume: 19, Issue:2

Topics: Animals; Antineoplastic Agents; Apoptosis; Blood-Brain Barrier; Brain Neoplasms; Carbazoles; Cell Proliferation; Dacarbazine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Female; Glioblastoma; High Mobility Group Proteins; Humans; Mice; Mice, Nude; Temozolomide; Transcriptional Elongation Factors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2017